0
0
New Delhi, August 19, 2025 — In a significant development for India’s pharmaceutical sector, Zydus Lifesciences Limited has encountered a regulatory roadblock in its quest to advance clinical trials for its much-anticipated Measles, Mumps, Rubella, and Varicella (MMRV) vaccine. The Subject Expert Committee (SEC) on Vaccines under the Central Drugs Standard Control Organisation (CDSCO) has directed Zydus to first conduct and submit a Phase I clinical trial protocol in healthy adults for its new vaccine formulation before proceeding with larger studies in children.
The directive comes in the wake of a Zydus proposal for a Phase II/III, multicentre, randomized, controlled trial comparing its MMRV vaccine with an established vaccine from GlaxoSmithKline Biologicals, aimed at healthy children aged 15–18 months.
According to documents from the SEC meeting held on July 25, 2025, several issues were flagged by the committee:
-
The Phase I trial permission was originally granted in 2015, but the study report was submitted only recently, leading to queries about the delay.
-
The committee noted discrepancies between the formulations used in Phase I and those planned for Phase II/III, specifically in terms of inactive ingredients and manufacturing processes.
-
Justification was requested for the absence of an initial Phase I protocol in healthy adults for the new formulation and for the limited sample size in the proposed Phase II/III pediatric study.
-
Additionally, the committee observed that the primary objective of “non-inferiority” was not incorporated in the current trial protocol.
After reviewing Zydus’s application, the SEC concluded that progression to pediatric studies with the new formulation would not be permitted without adequate justification and data from a Phase I adult trial.
This development marks a crucial checkpoint in India’s regulatory process for new and reformulated vaccines, ensuring that any significant formulation changes are backed by rigorous safety data before trials expand to vulnerable populations like infants and young children.
Disclaimer: This article is intended for informational purposes only and should not be construed as medical or regulatory advice. Any actions or decisions should be based on consultation with relevant authorities and health professionals.
Reference: “Regulatory Roadblock for Zydus: CDSCO Panel Halts MMRV Vaccine Trial, Seeks Adult Data,” Medical Dialogues, August 2025.
